Covestor’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Covestor’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-77	Closed	–	–	2785
2022 Q4	$0	Buy	77 +34	+79%	+$45	﹤0.01%	2805
2022 Q3	$0	Buy	+43	New	+$98	﹤0.01%	2825

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Covestor's SRNE Position: Q1 2023 in Review

Covestor sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 77 shares.

Covestor first reported a position in SRNE in Q3 2022 and held it in 2 quarters. The position peaked at $0 in Q4 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Covestor reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Covestor sold 77 Sorrento Therapeutics, Inc. shares in Q1 2023.
Covestor first reported a position in Sorrento Therapeutics, Inc. in Q3 2022 and held it in 2 quarters.
Covestor's Sorrento Therapeutics, Inc. position peaked at $0 in Q4 2022.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Covestor's 13F filing for Q1 2023, filed 15 May 2023.